January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January ...

The stock value and growth potential of a biotech firm depend on the type of diseases it treats. This might also include the research that the firm does as it supports other companies, diseases or ...

But local biotech leaders see signs of change in 2025 ... Ubaghs Carrión sees a few trends in the types of deals being made. For one, he said most of the deals (including IDRx and Scorpion ...

Alongside the flood of investment into biotechs working on potential COVID-19-related products, all types of biotech financing became easier to access, providing a major boost to companies looking ...

New recruits find the biotech field attractive because it mirrors their own characteristics. In the grand public narrative, biotech has been imbued with several clear strengths that distinguish it ...

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...